US 11,939,285 B2
4-hydroxybutyric acid analogs
Roger D. Tung, Lexington, MA (US)
Assigned to SUN PHARMACEUTICAL INDUSTRIES, INC., Princeton, NJ (US)
Filed by Concert Pharmaceuticals, Inc., Lexington, MA (US)
Filed on Oct. 29, 2021, as Appl. No. 17/514,416.
Application 17/514,416 is a continuation of application No. 16/739,422, filed on Jan. 10, 2020, granted, now 11,161,798.
Application 16/739,422 is a continuation of application No. 15/810,526, filed on Nov. 13, 2017, granted, now 10,532,971, issued on Jan. 14, 2020.
Application 15/810,526 is a continuation of application No. 14/732,859, filed on Jun. 8, 2015, granted, now 9,815,763, issued on Nov. 14, 2017.
Application 14/732,859 is a continuation of application No. 13/914,127, filed on Jun. 10, 2013, granted, now 9,051,261, issued on Jun. 9, 2015.
Application 13/914,127 is a continuation of application No. 13/265,609, granted, now 8,461,197, issued on Jun. 11, 2013, previously published as PCT/US2010/031981, filed on Apr. 22, 2010.
Claims priority of provisional application 61/287,561, filed on Dec. 17, 2009.
Claims priority of provisional application 61/214,382, filed on Apr. 23, 2009.
Prior Publication US 2022/0162146 A1, May 26, 2022
Int. Cl. A61K 31/19 (2006.01); A61K 31/18 (2006.01); A61K 31/197 (2006.01); A61K 31/381 (2006.01); A61K 45/06 (2006.01); C07B 59/00 (2006.01); C07C 59/01 (2006.01); C07C 69/675 (2006.01); A61K 31/195 (2006.01)
CPC C07C 59/01 (2013.01) [A61K 31/19 (2013.01); A61K 31/381 (2013.01); A61K 45/06 (2013.01); C07B 59/001 (2013.01); C07C 69/675 (2013.01); A61K 31/195 (2013.01); C07B 2200/05 (2013.01)] 11 Claims
 
1. A compound of the Formula B:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
A1 is —CH2—C(O)OR2′;
R2′ is hydrogen; deuterium; —C1-4 alkyl optionally substituted with phenyl; —(C3-6 cycloalkyl) optionally substituted with phenyl or methyl; —CH2—(C3-6 cycloalkyl) wherein the C3-6 cycloalkyl is optionally substituted with phenyl; phenyl; or biphenyl;
X1 is hydrogen;
each Y is independently selected from hydrogen and deuterium, wherein at least one Y is deuterium; and
wherein each position designated as deuterium has a deuterium incorporation of at least 90%.